- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05029076
Human Bioequivalence Test of Liraglutide Injection
30. august 2021 oppdatert av: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
To evaluate the bioequivalence of The liraglutide injection produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Victoza® produced by Novo Nordisk (China) Pharmaceutical Co., Ltd for single dose in healthy subjects,so as to provide reference for clinical evaluation and clinical medication;To observe the safety of the test preparation liraglutide injection and the reference preparation Victoza ® in healthy subjects.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
28
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Affiliated Hospital of Changchun University of Traditional Chinese Medicine
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 60 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Sign the informed consent form before the trial, fully understand the trial purpose, process and possible adverse reactions;
- Able to complete the study according to the requirements of protocol;
- Aged between 18 and 60 years old, both men and women;
- Male ≥50kg, female ≥45kg,body mass index(BMI)=weight (kg)/height 2 (m2), BMI is 18-28 kg/m2 (including the critical value);
- No mental abnormalities, no history of cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system or metabolic abnormalities;
- Normal or abnormal vital signs, physical examination, laboratory examination, electrocardiogram, and imageological examination have no clinical significance;
- The female blood pregnancy test is not pregnant, and the subjects (including male subjects) have no pregnancy plan and voluntarily take effective contraceptive measures from 2 weeks before administration to at least 3 months after the last use of the study drug. See the appendix for specific contraceptive measures.
Exclusion Criteria:
- Previous disease of the neuropsychiatric system, respiratory system, cardiovascular system, digestive system, hemo-lymphatic system, liver and kidney dysfunction, endocrine system, musculoskeletal system, or other disease that the investigator determines may affect drug metabolism or safety;
- Have a history of fainting needles, fainting blood;
- Known allergy to Liraglutide and its metabolites or any of the excipients of the formulation;
- Those who smoked more than 5 cigarettes per day during the 3 months before the trial.
- History of drug and/or alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 360 ml of beer or 45 ml of 40% alcoholic spirits or 150 ml of wine);
- Donated blood or lost a lot of blood (> 450 ml) within 2 months before taking the study drug ;
- Have taken any drug that changes liver enzyme activity 28 days before taking the study drug (such as liver drug enzyme inhibitor chlorpromazine, cimetidine, ciprofloxacin, metronidazole, etc.; liver drug enzyme inducer barbital Drugs, carbamazepine, rifampicin, dexamethasone, etc.);
- Have taken any prescription, over-the-counter, vitamin product or herbal medicine within 1 month prior to the use of the study drug;
- During the trial it is necessary to use tobacco, alcohol, and caffeine-containing drinks, or certain foods that may affect metabolism (such as grapefruit, grapefruit juice, etc.), or major changes in diet or exercise habits before the test, or other effects that affect drug absorption, Factors such as distribution, metabolism, excretion, etc;
- Have taken the study drug or participated in the drug clinical trial within 2 months before taking the study drug;
- Positive for hepatitis (including hepatitis B and C), HIV or syphilis at screening;
- Female subjects are breastfeeding or have a positive serum pregnancy result during the screening period or during the test;
- Those who have been screened positive for drugs or have a history of drug abuse in the past five years or have used drugs in the 3 months before the trial;
- Blood collection is difficult or cannot tolerate venipuncture blood collection;
- Acute illness during the screening phase or before study medication;
- The subject is unable or can not comply with ward management regulations;
- The subject is unable to complete the study due to personal reasons;
- Other cases judged by researchers to be unsuitable for selection.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Liraglutide injection + Victoza
Subjects receive liraglutide injection in the first cycle and Victoza in the second cycle.
|
Human glucagon-like peptides-1 analogue
Human glucagon-like peptides-1 analogue
|
Eksperimentell: Victoza +Liraglutide injection
Subjects receive Victoza in the first cycle and liraglutide injection in the second cycle.
|
Human glucagon-like peptides-1 analogue
Human glucagon-like peptides-1 analogue
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Maximum (peak) plasma drug concentration(Cmax)
Tidsramme: 0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Maximum (peak) plasma drug concentration
|
0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Time to reach maximum (peak) plasma concentration following drug administration (Tmax)
Tidsramme: 0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Time to maximum concentration
|
0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Area under the plasma concentration-time curve from time zero to time t (AUC0-t)
Tidsramme: 0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
The area under the plasma concentration curve from 0 to infinity
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Terminal disposition rate constant/terminal rate constant (λz)
Tidsramme: 0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent end elimination rate constant
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Elimination half-life (t1/2)
Tidsramme: 0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
The time required for the highest concentration of the drug in plasma to decrease by half
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent total clearance of the drug from plasma after oral administration (CL/F)
Tidsramme: 0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent total body clearance
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent volume of distribution after non-intravenous administration (Vd/F)
Tidsramme: 0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent volume of distribution
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Bioavailability (systemic availability of the administered dose)
Tidsramme: 0 hour(pre-dose, within 60mins) to 72 hours after administration on day1 and day 15.
|
Relative bioavailability
|
0 hour(pre-dose, within 60mins) to 72 hours after administration on day1 and day 15.
|
Adverse Event, Serious Adverse Event and Drug Combination
Tidsramme: up to day 15
|
Monitor the safety indicators of subjects during the trial
|
up to day 15
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
body temperature
Tidsramme: 1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
abnormal body temperature
|
1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
pulse
Tidsramme: 1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
abnormal pulse
|
1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
blood pressure
Tidsramme: 1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
abnormal blood pressure
|
1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
clinical symptoms
Tidsramme: From the screening period to day 18 after the first administration
|
Any discomfort spontaneously reported by the subject
|
From the screening period to day 18 after the first administration
|
The Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (physical examination)
Tidsramme: From the screening period to day 18 after the first administration
|
Monitor the safety indicators of subjects during the trial,For example: skin, mucous membrane, head (head, eyes, ears, nose, mouth), neck, chest (chest, breast, lung, heart), abdomen (liver, gallbladder, spleen, kidney, bladder), spine, limbs, nervous system, lymph nodes, etc,and calculate the Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
|
From the screening period to day 18 after the first administration
|
The Number of participants with abnormal laboratory examinations
Tidsramme: From the screening period to day 18 after the first administration
|
laboratory examination, such as liver function, kidney function, coagulation function, blood routine, urine routine
|
From the screening period to day 18 after the first administration
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
21. mai 2019
Primær fullføring (Faktiske)
1. juni 2019
Studiet fullført (Faktiske)
1. juli 2019
Datoer for studieregistrering
Først innsendt
24. august 2021
Først innsendt som oppfylte QC-kriteriene
30. august 2021
Først lagt ut (Faktiske)
31. august 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
31. august 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
30. august 2021
Sist bekreftet
1. august 2021
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ZDTQ-BE-2019-LLLT
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 2 diabetes
-
Jin-Hee AhnAsan Medical CenterUkjentHER-2 genamplifikasjon | HER-2 Protein Overekspresjon
-
The University of Tennessee, KnoxvilleFullførtMattelærere (2.–8. klasse) | Mattestudenter (2.–8. klasse)Forente stater
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.UkjentSolid svulst | HER-2 genamplifikasjon | HER2 genmutasjon | HER-2 Protein OverekspresjonKina
-
PowderMedFullført
-
Argorna Pharmaceuticals Co., LTDFullført
-
Argorna Pharmaceuticals Co., LTDFullført
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Aktiv, ikke rekrutterende
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Aktiv, ikke rekrutterende
-
Arcturus Therapeutics, Inc.Avsluttet
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsFullført
Kliniske studier på Liraglutide injection
-
GE HealthcareRekrutteringOnkologi | Ondartet solid svulstNederland
-
Dermatology Cosmetic Laser Medical Associates of...SanofiTilbaketrukketAvmagring | LipodystrofiForente stater
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.FullførtIskemisk hjerneslagKina
-
HealthBeacon PlcModena Allergy & AsthmaPåmelding etter invitasjon
-
Hemera BiosciencesTilbaketrukketGeografisk atrofi | Tørr aldersrelatert makuladegenerasjon | Genterapi | Intravitreal injeksjon
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing University of Chinese MedicineUkjentHånd-, fot- og munnsykdomKina
-
Marval Pharma Ltd.AvsluttetFriske FrivilligeForente stater
-
Novo Nordisk A/SFullført
-
Jiangsu HengRui Medicine Co., Ltd.RekrutteringInfertile kvinnelige forsøkspersoner som gjennomgår kontrollert ovarial hyperstimulering for å undertrykke for tidlig LH-stigning og forhindre tidlig eggløsningKina
-
Woman'sNovo Nordisk A/SFullførtPolycystisk ovariesyndrom | Pre Diabetes | Fedme AndroidForente stater